Hikma Pharmaceuticals (LON:HIK) Price Target Cut to GBX 865 by Analysts at

Hikma Pharmaceuticals (LON:HIK) had its target price decreased by from GBX 1,060 ($14.20) to GBX 865 ($11.58) in a research report sent to investors on Friday, November 10th. currently has a reduce rating on the stock.

A number of other brokerages have also weighed in on HIK. Citigroup restated a neutral rating and issued a GBX 1,350 ($18.08) target price on shares of Hikma Pharmaceuticals in a research note on Thursday, August 24th. J P Morgan Chase & Co restated a neutral rating on shares of Hikma Pharmaceuticals in a research note on Friday, September 29th. Peel Hunt reiterated a hold rating and issued a GBX 2,150 ($28.79) price target on shares of Hikma Pharmaceuticals in a report on Thursday, August 17th. Stifel Nicolaus cut Hikma Pharmaceuticals to a hold rating and decreased their price target for the company from GBX 2,300 ($30.80) to GBX 1,320 ($17.68) in a report on Tuesday, August 29th. Finally, Numis Securities reiterated an add rating and issued a GBX 1,560 ($20.89) price target on shares of Hikma Pharmaceuticals in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of GBX 1,321.91 ($17.70).

Hikma Pharmaceuticals (LON HIK) traded down GBX 19 ($0.25) during trading on Friday, reaching GBX 1,028 ($13.77). The company’s stock had a trading volume of 1,217,648 shares, compared to its average volume of 1,020,000. Hikma Pharmaceuticals has a 1 year low of GBX 906.50 ($12.14) and a 1 year high of GBX 2,346 ($31.42).

ILLEGAL ACTIVITY NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/markets/hsbc-holdings-plc-cuts-hikma-pharmaceuticals-plc-hik-price-target-to-gbx-865/1774551.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.